drugset / Trial / NCT01786915

Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days

NCT01786915

Phase 1 Completed 30 enrolled Stealth BioTherapeutics Inc.
RandomizedParallel-groupTriple-blindBasic science

Summary

The purpose of this study is to assess the study medication blood levels after administration of a repeat oral capsules (one capsule each day for seven days) of Bendavia at one of two dose levels. The effects of Bendavia on the volunteers will also be assessed.

Timeline

Start
2013-02
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Elamipretide Peptide 10 mg Oral
Subject Elamipretide Peptide 50 mg Oral

Indications

No indication recorded.